Oncology
2 drugs are in development for Metastatic Urothelial Carcinoma.
- Companies
- 2
- Clinical trials
- 17
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Urothelial Carcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| TYRA-300 | Tyra Biosciences, Inc. (TYRA) |
Phase 1(1)
| Drug | Company |
|---|---|
| gb-4362 | Generate Biomedicines Inc. (GENB) |
About this indication
Metastatic Urothelial Carcinoma context
Oncology·MeSH: Carcinoma, Transitional Cell (D002295)
Prevalence
61.0 / 100K
Incidence
18.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Metastatic Urothelial Carcinoma?
BioSniper tracks 2 drugs in development for Metastatic Urothelial Carcinoma across 2 companies.
How many clinical trials target Metastatic Urothelial Carcinoma?
There are 17 clinical trials targeting Metastatic Urothelial Carcinoma tracked by BioSniper.
What is the prevalence of Metastatic Urothelial Carcinoma?
The estimated prevalence of Metastatic Urothelial Carcinoma is approximately 61.0 per 100,000 population.